Advisors Asset Management Inc. Purchases New Holdings in Pfizer Inc. $PFE

Advisors Asset Management Inc. purchased a new position in shares of Pfizer Inc. (NYSE:PFE – Free Report) during the third quarter, HoldingsChannel.com reports. The fund purchased 780,185 shares of the biopharmaceutical company’s stock, valued at approximately $22,251,000.

A number of other hedge funds also recently made changes to their positions in the stock. Russell Investments Group Ltd. grew its stake in shares of Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock valued at $132,365,000 after acquiring an additional 745,213 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in Pfizer by 10.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after purchasing an additional 232,528 shares during the period. Leuthold Group LLC bought a new stake in Pfizer in the 2nd quarter valued at about $4,887,000. Park National Corp OH grew its position in shares of Pfizer by 332.1% during the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock worth $5,829,000 after purchasing an additional 186,053 shares in the last quarter. Finally, 111 Capital acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $3,706,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Roundup

Investors following PFE have been watching these news items:

  • Positive Sentiment: A recent analysis said Pfizer’s launched and acquired products grew 32% in the third quarter, suggesting newer medicines are gaining traction and could help offset pressure on older products and COVID-related revenue. Article: Pfizer's Launched and Acquired Drugs Grew 32% in Q3
  • Neutral Sentiment: Pfizer also reported updates to clinical studies, including an RSV booster study in older adults and a Phase 3 study of berobenatide. The entries provide no trial results, so they offer limited evidence of near-term commercial impact. Article: Pfizer Advances RSV Booster Study in Older Adults
  • Negative Sentiment: Technical indicators cited in a market update showed weak near-term momentum, with daily signals at “Strong Sell” and hourly signals at “Sell.” That may weigh on sentiment even as Pfizer pursues pipeline growth. Article: Pfizer near-term support and resistance levels

Pfizer Price Performance

Shares of PFE opened at $27.41 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.10 and a current ratio of 1.42. The firm has a market cap of $156.25 billion, a PE ratio of 9.46, a price-to-earnings-growth ratio of 1.90 and a beta of 0.31. The business’s 50 day moving average price is $28.82 and its two-hundred day moving average price is $27.03. Pfizer Inc. has a 52-week low of $23.62 and a 52-week high of $31.44.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The company had revenue of $16.58 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the prior year, the firm earned $0.87 EPS. The business’s revenue was down .4% on a year-over-year basis. On average, equities analysts anticipate that Pfizer Inc. will post 3.04 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. Pfizer’s payout ratio is currently 245.71%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Scotiabank raised their target price on shares of Pfizer from $33.00 to $35.00 and gave the stock a “sector outperform” rating in a report on Wednesday, November 4th. Citigroup boosted their price target on Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. Guggenheim raised their price objective on Pfizer from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Cantor Fitzgerald lifted their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. Finally, FBN Securities set a $34.00 target price on Pfizer in a research report on Friday, November 6th. Six investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $30.32.

Check Out Our Latest Stock Report on Pfizer

Pfizer Company Profile

(Free Report)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.